Genetics Expert Witnesses in West Virginia

This renowned expert is currently the Chair of the department of Family and Geriatric Medicine for a major university in Kentucky, where she also works as a Professor of Obstetrics & Gynecology, Bioengineering, Epidemiology & Population Health, and Health Promotion and Behavioral Sciences. The expert specializes in human papillomavirus and its associated diseases, as well as colposcopy. She acted as the Principal Investigator of the clinical trials for leading HPV vaccines Gardasil and Cervarix. The expert has appeared frequently in national outlets commenting on the safety and efficacy of HPV vaccines. He has a B.S. in Chemical Engineering and an M.S. in Polymerics from M.I.T., as well as an M.D. and an M.P.H. in Biostatistics & Epidemiology from the University of Kansas Medical School. The expert is board certified by the American Board of Family Practice and is licensed to practice in Missouri, Kansas, New Hampshire, Vermont, and Kentucky.

This highly qualified expert has extensive experience in the fields of cancer, biomedical research, pre-clinical animal research and ethics, and drug development, among others. After earning his BS from East Carolina University and his MS from The University of North Carolina at Greensboro, this expert completed his PhD in genetics and molecular biology at The University of North Carolina, Chapel Hill. He also went on to complete his MBA in biosciences management at North Carolina State University. This expert is an active member of the American Association of Immunologists, the Society for Leukocyte Biology, and the American Association for Cancer Research. In addition to being extensively published, he is the current associate editor of Frontiers in Immunology and Frontiers in Microbiology. Further, this expert has been engaged in a variety of university program development and research operations leadership roles throughout his career. Among his former roles, he has served as a research analyst with the Center for Human Genetics at Duke University Medical Center, a research associate for microbiology and immunology at The University of North Carolina Chapel Hill, and as an assistant professor of inflammatory diseases at Virginia-Maryland College of Veterinary Medicine. This expert currently maintains two assistant professorships at a public medical school in Virginia, in addition to his primary role as an associate professor of inflammatory diseases at a veterinary medicine education school.

This highly qualified expert currently serves as Assistant Professor of Pediatrics and Affiliate Faculty of the Molecular Genetics Department at a major medical university. In addition to a Ph.D. in Cell Biology from Duke University Medical Center, he received a B.S. in Physiology and Neurobiology and a M.S. in Developmental Neurobiology from the University of Maryland. A member of both the Society for Developmental Biology and the American Society for Human Genetics, he has authored several publications on developmental biology. He has over 15 years of experience in the genetics of congenital defects.

A 17-year veteran of the U.S. Food and Drug Administration (FDA), this expert served as the Regulatory Counsel to the Associate Commissioner for Regulatory Affairs, and previously, in scientific, inspectional, compliance and criminal and civil enforcement capacities as an FDA Consumer Safety Officer (CSO), Compliance Officer (CO), a Senior Special Agent (SA) with the Office of Criminal Investigations (OCI) and as an analytical regulatory microbiologist. During his last three years at FDA he spearheaded the agency's integration efforts with Customs and USDA on crosscutting interagency enforcement and operational issues; served as the FDA's point-person in managing the intersection of imports and FDA's new bioterrorism regulations; established joint agency and industry working groups to evaluate counterfeiting and tampering risks to food and drug distribution supply chains; was the agency lead in its strategic planning efforts to reinvent the FDA's import programs; wrote the initial statement of work and acted as program manager over the FDA's new PREDICT, risk-based electronic entry screening system; and directed the development of the FDA's agency-wide Risk-based Import Strategic Plan designed to improve compliance of foods, dietary supplements, drugs, medical devices, cosmetics, and biological products imported into the U.S. As CEO of a FDA consulting firm and Founder of an affiliated law firm, he currently represents domestic and foreign companies of all sizes, assisting them in identifying USDA, FDA, Federal Trade Commission (FTC), Environmental Protection Agency (EPA), and state requirements. He focuses his practice on FDA matters, including but not limited to: matters relating to FDA inspections, FDA criminal, regulatory and administrative enforcement actions for medical devices, drugs, cosmetics, alcohol, tobacco, dietary supplements, and foods.